Liu Shu: Clinical Trials

2 recruiting, 1 unknown. 2 Phase 1, 2 Phase 2, 1 Not applicable.

By phase and status

Phase	Trials	Status
Phase 1	2	Recruiting 2
Phase 2	2	Recruiting 2
Not applicable	1	Unknown 1

Follow Liu Shu: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Epirubicin and cyclophosphamide followed by paclitaxel oral solution - Triple -Negative Breast Cancer	Phase 1 / Phase 2	Recruiting	Liu Shu	30	2026-07-30	2026-08-04
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Paclitaxel oral solution plus Trastuzumab and Pertuzumab - HER2 + Breast Cancer	Phase 1 / Phase 2	Recruiting	Liu Shu	30	2026-07-29	2026-08-04
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer Dalpiciclib and Letrozole Combined With Anlotinib - Breast Cancer	Not applicable	Unknown	Liu Shu	30	2024-10-31	2024-09-20

Conditions studied

Breast Neoplasms (2)  ·  Triple Negative Breast Neoplasms (1)

Interventions

Epirubicin (1)  ·  Paclitaxel (1)  ·  Trastuzumab (1)  ·  anlotinib (1)  ·  dalpiciclib (1)  ·  pertuzumab (1)

Countries

China (2)